Prices for prescription pharmaceuticals were nearly 3% higher during the third quarter of 1997 than during the third quarter of 1996, according to IMS America's Quarterly Pricing Report.
Prices for prescription pharmaceuticals were nearly 3% higher during the third quarter of 1997 than during the third quarter of 1996, according to IMS America's Quarterly Pricing Report.
IMS America, Plymouth Meeting, PA, attributed the 2.9% increase to a significantly slower decline in the prices of generics and increases in prices of branded products.
Overall prices for generics dropped at a rate of 6.4% compared with a year ago, while prices of branded prescription medicines rose 3.8%.
According to Myron Holubiak, general manager of IMS America's consulting arm, The Plymouth Group, total prescription sale growth in retail pharmacies, hospitals, clinics, staff-model HMOs, long-term care facilities and federal facilities was 17.3% higher than it was a year ago.
"Non-price factors, such as increased volume and mix of products, combined with exceptional growth in new products appeared to be dominant industry drivers," Holubiak said. "Several significant new products introduced late last year have already broken into the top 100 best-selling drugs."
He added that third-party coverage for prescription products increased, and increased coverage is associated with increased demand for prescription products. Medicare beneficiaries, who are rapidly joining managed care plans, play a major role in this growth. According to IMS America, Medicare beneficiaries increase drug expenditures nearly twofold when they have greater access to a prescription drug plan. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.